Evidence map›Paper›PMID 29843157›Full record

ArticleOncology2018

Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma.

Fatemeh G Amlashi, Xuemei Wang, Raquel E Davila, Dipen M Maru, Manoop S Bhutani, Jeffrey H Lee, Brian R Weston, Dilsa Mizrak Kaya, Maria Vassilakopoulou, Kazuto Harada and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Fatemeh G AmlashiDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Xuemei WangDepartment of Biostatics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Raquel E DavilaDepartment of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Dipen M MaruDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Manoop S BhutaniDepartment of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jeffrey H LeeDepartment of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Brian R WestonDepartment of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Dilsa Mizrak KayaDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Maria VassilakopoulouDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kazuto HaradaDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Mariela A Blum MurphyDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
David C RiceDepartment of Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wayne L HofstetterDepartment of Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Marta DavilaDepartment of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Quynh-Nhu NguyenDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jaffer A AjaniDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Funding

Prediction of Pathologic Complete Response by Gene Expression Profiling in EsophaR01CA138671 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AJANI, JAFFER A. · 2010 to 2014
$1.5M
Inhibition of Hedgehog Signaling in Gli-1+Adeno CA of the Esoph or GE junctionR01CA172741 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AJANI, JAFFER A. · 2013 to 2017
$1.4M
Molecular Biomarkers as Classifiers to Individualize Therapy of Esophagus CancerR21CA129906 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AJANI, JAFFER A. · 2009 to 2010
$367k
Molecular Markers of Response to Chemoradiation in Localized Esophageal CancerR21CA127672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AJANI, JAFFER A. · 2008 to 2009
$312k
NCI NIH HHS R01 CA138671NCI NIH HHS R01 CA172741NCI NIH HHS R21 CA127672NCI NIH HHS R21 CA129906
6 · The paper itself

Abstract

introductionBarrett's esophagus (BE) may be present in patients with esophageal adenocarcinoma (EAC) after bimodality therapy (BMT). There is no specific guidance for follow-up of these patients with regard to the presence of BE or dysplasia. In this study, we assessed the outcomes of patients who, after BMT, had BE and those who did not.

methodPatients with EAC who had BMT were identified and analyzed retrospectively in two groups, with and without BE. We compared patient characteristics and outcome variables (local, distant, and no recurrence).

resultsOf 228 patients with EAC, 68 (29.8%) had BE before BMT. Ninety-eight (42.9%) had BE after BMT, and endoscopic intervention was done in 11 (11.2%). With a median follow-up of 37 months, the presence of post-BMT BE was not significantly associated with overall survival (OS) and local recurrence-free survival (LRFS). Similarly, endoscopic intervention was not significantly associated with OS and LRFS. Fifty (73.5%) patients with BE before BMT had BE after BMT (p < 0.0001).

conclusionThe presence of BE after BMT was not associated with increased risk of local recurrence. The local recurrence rate was not influenced by endoscopic intervention. Prospective studies are warranted to generate guidance for intervention, if necessary, for this group of EAC patients.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overBarrett EsophagusChemoradiotherapyCombined Modality TherapyDisease-Free SurvivalDisease ProgressionEndoscopyEsophageal NeoplasmsEsophagusFemaleHumansMaleMiddle AgedBarrett’s esophagusEndoscopyEsophageal adenocarcinomaRecurrenceSurvival

Identifiers

PMID29843157
PMCPMC6067962

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.